Vascepa to Accelerate Lipoprotein Uptake and Elimination

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 11, 2016

Primary Completion Date

August 31, 2018

Study Completion Date

June 30, 2021

Conditions
Lipid DisorderTriglycerides HighDyslipidemias
Interventions
DRUG

Icosapent Ethyl 1000 MG [Vascepa]

Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA). The empirical formula of icosapent ethyl is C22H34O2 and the molecular weight is 330.51. The chemical name for icosapent ethyl is ethyl all-cis-5,8,11,14,17-icosapentaenoate.

Trial Locations (1)

19104

Perelman School of Medicine at the University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amarin Pharma Inc.

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT03885661 - Vascepa to Accelerate Lipoprotein Uptake and Elimination | Biotech Hunter | Biotech Hunter